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Florida red tide is a harmful algal bloom
caused by the dinoflagellate Karenia brevis
(previously Gymnodinium breve). K. brevis pro-
duces at least nine structurally related poly-
ether brevetoxins (PbTxs; Baden 1989; Baden
et al. 1995; Pierce and Kirkpatrick 2001),
which are lipid-soluble, fused polyethers with
molecular weights of approximately 900 Da.
During red tide events, toxins released from
disrupted organisms are concentrated in seawa-
ter droplets that subsequently can become
aerosolized (Pierce et al. 1990, 2003). Onshore
winds then carry these aerosols inland, where
exposed individuals report both upper and
lower airway symptoms, such as nonproduc-
tive cough, shortness of breath, rhinorrhea,
and sneezing (Asai et al. 1982; Backer et al.
2003; Kirkpatrick et al. 2004). There is a sug-
gestion that the frequency of these adverse res-
piratory events is increased in “susceptible
populations,” that is, in those with pre-existing
airway disease, as indicated from a clinical sur-
vey where 80% of patients with bronchial
asthma were reportedly affected during a red
tide event, with some having overt asthma
attacks (Asai et al. 1982).
Although the data from these clinical sur-
veys and our own ﬁeld studies (Backer et al.
2003; Baden and Tomas 1988; Fleming et al.
2005; Kirkpatrick et al. 2004; Pierce et al.
1992, 2003) indicate that aerosolized toxins
are respiratory irritants and that the effects
may be more severe in asthmatics, there is a
paucity of data examining the effects of
aerosolized toxin in asthmatic airways under
controlled conditions. To address this prob-
lem, we initially studied the airway responses
to inhaled PbTxs in a sheep model of asthma
(Abraham et al. 2005). This model shares
many characteristics of the disease in humans,
including the development of early airway
responses (EAR) and late airway responses
(LAR) and postantigen-induced airway hyper-
responsiveness (AHR) after inhalation chal-
lenge with Ascaris suum antigen (Abraham
2000). The model also demonstrates nonspe-
ciﬁc bronchial hyperresponsiveness to a variety
of agents, and we have previously used it to
study the pulmonary consequences of pollu-
tant exposures (Abraham et al. 1980, 1981).
Furthermore, the antigen-induced effects in
this model can be ameliorated with the cur-
rent armamentarium of clinically available
asthma medications, including glucocorticos-
teroids, β2 adrenergic agents, and leukotriene
antagonists (Abraham 2000). Collectively, the
characteristics of the model suggest that it can
be used as a surrogate for patients with com-
promised airways to study the effects of
inhaled toxin.
In our initial studies, allergic sheep that
inhaled environmentally relevant concentra-
tions (picogram per milliliter) of lysed
cultures of K. brevis (i.e., crude brevetoxins,
which contains all toxins and cell debris) or
puriﬁed PbTx-2 or PbTx-3 developed signiﬁ-
cant bronchoconstriction (Abraham et al.
2005). The magnitude of the response was
similar for the three toxins (Abraham et al.
2005). Previous in vitro studies using canine
tracheal and human bronchial smooth muscle
(Asai et al. 1982; Shimoda et al. 1988),
demonstrated that brevetoxin-induced con-
tractile effects can be blocked with atropine
but not with a histamine antagonist, suggest-
ing that toxin-induced constriction results
from stimulation of parasympathetic postgan-
glionic neurons. In contrast to the prior
in vitro ﬁndings, however, our in vivo studies
showed that protective effects were achieved
with the mast cell stabilizer cromolyn sodium
and the histamine H1-antagonist diphenhy-
dramine. These data support a role for a hist-
amine H1-mediated pathway contributing to
the bronchoconstrictor response in vivo
(Abraham et al. 2005). Because mast cells and
basophils are the most prominent source of
histamine in the airways, our ﬁndings suggest
that toxin, either directly or indirectly, causes
mast cell/basophil activation. Such a mecha-
nism could in part explain the reported
increased incidence of asthma attacks after
natural red tide episodes.
Another factor that could play a role in
asthma exacerbations is the generation of
kinins in the airway. The pattern of airway
responses and the pharmacologic proﬁle seen
with inhaled toxin (Abraham et al. 2005) are
similar to those seen previously by us with
inhaled bradykinin (Abraham et al. 1991).
Increased airway kinin levels occur after expo-
sure to a variety of noxious stimuli (Lauredo
et al. 2003), including allergen, ozone, bacter-
ial products, and metabisulﬁte (Forteza et al.
1994, 1999; Mansour et al. 1992), and are
associated with bronchoconstriction, AHR,
and lung neutrophilia; all of these responses
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During a Florida red tide, brevetoxins produced by the dinoflagellate Karenia brevis become
aerosolized and cause airway symptoms in humans, especially in those with pre-existing airway dis-
ease (e.g., asthma). To understand these toxin-induced airway effects, we used sheep with airway
hypersensitivity to Ascaris suum antigen as a surrogate for asthmatic patients and studied changes in
pulmonary airﬂow resistance (RL) after inhalation challenge with lysed cultures of K. brevis (crude
brevetoxins). Studies were done without and with clinically available drugs to determine which
might prevent/reverse these effects. Crude brevetoxins (20 breaths at 100 pg/mL; n = 5) increased
RL 128 ± 6% (mean ± SE) over baseline. This bronchoconstriction was significantly reduced
(% inhibition) after pretreatment with the glucocorticosteroid budesonide (49%), the β2 adrenergic
agent albuterol (71%), the anticholinergic agent atropine (58%), and the histamine H1-antagonist
diphenhydramine (47%). The protection afforded by atropine and diphenhydramine suggests that
both cholinergic (vagal) and H1-mediated pathways contribute to the bronchoconstriction. The
response to cutaneous toxin injection was also histamine mediated. Thus, the airway and skin data
support the hypothesis that toxin activates mast cells in vivo. Albuterol given immediately after
toxin challenge rapidly reversed the bronchoconstriction. Toxin inhalation increased airway kinins,
and the response to inhaled toxin was enhanced after allergen challenge. Both factors could
contribute to the increased sensitivity of asthmatic patients to toxin exposure. We conclude that
K. brevis aerosols are potent airway constrictors. Clinically available drugs may be used to prevent
or provide therapeutic relief for affected individuals. Key words: animal models, asthma, brevetoxin,
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PbTx-3 (Zaias et al. 2004).
The evidence suggesting that toxin stimu-
lates mast cells/basophils and/or increases air-
way kinins heightens the importance of
understanding toxin effects in allergic airways.
Therefore, in this study we used allergic sheep
to study further the effects of inhaled toxin in
compromised airways. Speciﬁcally, we deter-
mined a) if toxin alone could induce airway
responses similar to that seen with allergen,
b) if preexposure to toxin could exacerbate
allergen-induced responses, and c) the effects of
clinically available drugs and experimental
pharmacologic agents on toxin-induced airway
constriction. In addition, we showed that toxin
activates skin mast cells and so provide further
support for the in vivo mast cell hypothesis.
Materials and Methods
Adult ewes (Quin Tindall, Okeechobee, FL)
that were naturally sensitive to A. suum anti-
gen and had demonstrated airway hypersensi-
tivity to this antigen were used (Abraham
2000). The animals were conscious and
restrained in a cart in an upright position
with their heads immobilized for the
described studies. Instrumentation was per-
formed under local anesthesia. The study was
conducted at Mount Sinai Medical Center
under the approval of the Mount Sinai
Medical Center Animal Research Committee.
Pulmonary resistance. These methods
have been reported in detail (Abraham et al.
1994, 2000, 2004). Brieﬂy, a balloon catheter
was advanced through one nostril into the
lower esophagus, and the animals were intu-
bated with a cuffed endotracheal tube
through the other nostril. Animals remained
intubated throughout the course of a particu-
lar experiment, but to avoid discomfort dur-
ing these studies, the cuff of the endotracheal
tube was inflated only during the measure-
ments of pulmonary resistance (RL) and dur-
ing delivery of nebulized agents. We have
shown previously that this intubation proce-
dure does not affect RL or airway responsive-
ness in these animals for periods of up to 9 hr
(Russi et al. 1984). Pleural pressure was
measured via the esophageal catheter. Lateral
pressure in the trachea was measured with a
side-hole catheter advanced through and
positioned distal to the tip of the endo-
tracheal tube. Transpulmonary pressure, the
difference between tracheal and pleural pres-
sure, was measured with a differential pres-
sure transducer. To measure RL, the proximal
end of the endotracheal tube was connected
to a pneumotachograph, and the signals of
flow and transpulmonary pressure were
recorded on a computer. Respiratory volume
was obtained by digital integration of
the ﬂow signal so that RL was calculated from
the transpulmonary pressure and flow, at
isovolumetric points. Analysis of 5–10 breaths
was used for each determination of RL.
Agents. Crude brevetoxins and purified
PbTx-3 were obtained from the Center for
Marine Science at the University of North
Carolina at Wilmington. Crude brevetoxin was
diluted in NH-15 buffer. PbTx-3 was first
diluted in a small volume of Alkamuls
(Emulphor EL-620: ethoxylated castor oil and
water; Chemtec Chemical Co., Chatsworth,
CA), followed by suspension in phosphate-
buffered saline (PBS). Atropine sulfate injec-
tion (Baxter Health Care, Deerfield, IL) was
given at a dose of 0.2 mg/kg, iv,; the histamine
H1-antagonist diphenhydramine hydrochlo-
ride (Elkins-Sinn Inc., Cherry Hill, NJ) was
diluted in PBS and given at a dose of 2 mg/kg,
iv. Albuterol sulfate inhalation solution
(2.5 mg/3 mL; Dey, Napa, CA) was given as
an aerosol. A. suum extract (Greer Diagnostics,
Lenoir, NC) was diluted with PBS to a concen-
tration of 82,000 protein nitrogen units/mL
and delivered as an aerosol (20 breaths/min).
The following agents were all obtained from
Sigma (St. Louis, MO): The bradykinin B2
receptor antagonist HOE-140 was diluted in
PBS, and given as an aerosol (400 nM/kg);
budesonide was ﬁrst diluted in 1 mL ethanol
and then in PBS to give a 1 mg/3 mL solution
and was given as an aerosol; carbamylcholine
(carbachol) was dissolved in PBS at concen-
trations of 0.25, 0.50, 1.0, 2.0, and
4.0% wt/vol and delivered as an aerosol. As
reported previously in detail (Abraham et al.
1994, 2004; Scuri et al. 2002), we used a
dosimeter-piston ventilator system with a
Raindrop nebulizer (Nelcor Puritan Bennett,
Carlsbad, CA) to deliver the aerosols directly
into the endotracheal tube only during inspi-
ration at a tidal volume of 500 mL and a rate
of 20 breaths/minute.
Assessment of nonspecific airway respon-
siveness. Airway responsiveness to carbachol
was determined from cumulative concentra-
tion–response curves as previously described
(Abraham et al. 1994, 2004; Scuri et al.
2002). RL was measured immediately after
inhalation of PBS and within 5 min after each
consecutive administration of 10 breaths of
increasing concentrations of carbachol (0.25,
0.5, 1.0, 2.0, and 4.0% wt/vol PBS). The
provocation test was discontinued when RL
increased > 400% from the post-PBS value or
after the highest carbachol concentration had
been administered. The cumulative carbachol
concentration (in breath units) that increased
RL by 400% over the post-PBS value
(PC400) was calculated by interpolation from
the dose–response curve. One breath unit was
defined as one breath of a 1% wt/vol carba-
chol aerosol solution. A decrease in the
PC400 indicates the development of AHR.
Airway responsiveness to PbTx-3. Baseline
RL was measured, and then the sheep were
challenged with 20 breaths of increasing
concentrations of PbTx-3: 0.1, 0.3, 1, and
10 pg/mL of PbTx-3. RL was measured within
5 min after the delivery of each concentration
of toxin.
Airway responses to toxin. Baseline RL
was measured, and then the sheep were
challenged with 20 breaths of 100 pg/mL of
crude brevetoxins. RL was measured immedi-
ately after challenge and then 15, 30, and
60 min after challenge. Responses to crude
brevetoxins alone were compared with the
responses obtained after treating the animals
with the histamine H1-antagonist diphenhy-
dramine, the anticholinergic agent atropine,
the glucocorticosteroid budesonide, or the
bradykinin B2 receptor antagonist HOE-140.
All drugs were given 30 min before chal-
lenge. Repeat challenges were separated by a
minimum of 48 hr. In a separate study,
albuterol aerosol was given immediately after
inhalation of crude brevetoxins to determine
if the drug could reverse the toxin-induced
bronchoconstriction. Drug doses chosen for
these studies were based on our previous use
of these compounds (Abraham 2000).
Allergen–PbTx-3 interaction. To deter-
mine if multiple exposures to PbTx-3
affected antigen-induced responses, we
challenged sheep in the morning with
20 breaths of 100 pg/mL PbTx-3 for 3 con-
secutive days and then on the fourth day
challenged the animals with allergen to
determine if the antigen-induced EAR,
LAR, and AHR were affected. For these
studies a baseline PC400 to carbachol was
determined 1–3 days before the start of
PbTx-3 exposures. One day after the last
PbTx-3 exposure (day 4), baseline RL was
measured, and then the sheep were chal-
lenged with antigen. RL was measured
immediately after, hourly for 1–6 hr after,
and then on the half-hour from 6.5 to 8 hr
after challenge. On the next day, the
postantigen PC400 was determined. The
results were compared with those obtained
without PbTx-3 exposure in the same sheep.
To determine if allergen challenge affected
the response to PbTx-3, a baseline PC400 to
carbachol and a concentration–response curve
to PbTx-3 were determined. One to 3 days
later, baseline RL was measured, and then the
sheep were challenged with antigen. RL was
measured immediately after, hourly for 1–6 hr
after, and then on the half-hour from 6.5 to
8 hr after challenge. On the next day, the
postantigen response to PbTx-3 was deter-
mined. Two to 3 hr later when RL had
returned to normal, the postantigen PC400 to
carbachol was measured. The changes in the
postchallenge compared with prechallenge
responses to PbTx-3 and PC400 were assessed
to determine if they were affected by the
allergen provocation.
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the potential for a generalized H1-mediated
response to toxin, we performed skin tests with
crude brevetoxins and pure PbTx-3 to deter-
mine if they would induce a wheal response
and if the response was histamine mediated
(Lucio et al. 1992; Molinari et al. 1995).
Immediate cutaneous responses (ICRs) were
induced by intradermal injections of 0.05 mL
of 5% wt/vol histamine, 100 pg/mL crude
brevetoxins, or PbTx-3 solutions using insulin
syringes with 28-gauge needles. These studies
were repeated, but the sheep were treated with
diphenhydramine (2 mg/kg, iv) 2 hr before
intradermal challenge or with atropine
(0.2 mg/kg, iv) 30 min before challenge. 
Statistical analysis. Overall effects of airway
responses with and without pharmacologic
intervention were analyzed with a multifactorial
analysis of variance for repeated measures. If the
null hypothesis was rejected, then Tukey’s post
hoc test was used to determine the statistical
significance of differences. In the event only
two treatments were compared, a paired t-test
was used. Analysis of the ICR was determined
as described previously by our group (Molinari
et al. 1995; Lucio et al. 1992). Wheal sizes were
measured 20 and 60 min after injection of
active test solutions. The surface area (mm2) of
the wheal was determined by measuring the
largest wheal diameter (D1) and its perpendicu-
lar (D2) and then calculating the surface area
using the equation Π[(D1 + D2)/4]2. Results
were compared by one-way analysis of variance
followed by Tukey’s post hoc test if the null
hypothesis was rejected. For all analyses, signiﬁ-
cance was accepted when p < 0.05 using a two-
tailed analysis. Values in the text and ﬁgures are
reported as mean ± SE.
Results
Airway responses to toxin with and without
pharmacologic intervention. Inhalation of
crude brevetoxins resulted in an immediate
bronchoconstriction (RL increased 128 ± 6%
over baseline), which then resolved over the
next 60 min (Figure 1). The constrictor
effects of toxin were signiﬁcantly reduced by
pretreating the animals with the anticholin-
ergic agent atropine (58% inhibition), the
glucocorticosteroid budesonide (49% inhibi-
tion), the β2 adrenergic agent albuterol
(71% inhibition), and the histamine
H1-antagonist diphenhydramine (47% inhi-
bition). The reduced response in the pres-
ence of either diphenhydramine or atropine
suggests that both cholinergic (vagal) and
H1-mediated pathways play a role in the
toxin-induced bronchoconstriction. It is
important to note that we previously showed
that the dose of atropine used in these stud-
ies does not block histamine-induced bron-
choconstriction (Abraham et al. 2005).
These results are consistent with histamine
stimulation of H1 receptors on nerves. The
protective effects of albuterol and budes-
onide are also consistent with the involve-
ment of mast cells/basophils because both
agents have been reported to reduce media-
tor release (Wanner et al. 1987). Although
albuterol can inhibit mediator release, its
primary action is to relax smooth muscle. As
illustrated in Figure 2, giving albuterol
immediately after toxin challenge causes a
rapid reversal of the response. The dual
action of albuterol may account for its
increased efficacy when compared with
diphenhydramine (Figure 1).
Figure 3 illustrates that HOE-140, a
bradykinin B2 receptor antagonist, signifi-
cantly reduces the toxin-mediated bron-
choconstriction. The 34% protection was
signiﬁcant when compared with the response
when the animals were untreated but is signif-
icantly less than that seen with atropine
(58%). These data indicate that, as with other
types of irritants, brevetoxin increases kinin
levels in the airways and that this inﬂamma-
tory mediator contributes to toxin-induced
airway responses.
Cutaneous responses to toxin. The in vivo
airway data support a role for a histamine
H1-mediated component in the bronchocon-
strictor response. To further investigate the
potential for a generalized H1-mediated event,
we performed skin tests with crude brevetox-
ins and pure PbTx-3. Both crude brevetoxins
and PbTx-3 induced an ICR, which was
reduced when the animals were pretreated
with the H1-antagonist diphenhydramine
(Figure 4). As expected, atropine had no
effect on the ICR (data not shown). Thus, the
collective data obtained with inhaled and
injected toxins support the hypothesis that
histamine H1-mediated pathways contribute
to the in vivo effects of toxin.
Allergen–toxin interactions. Our results
indicate that inhaled toxin induces histamine
and kinin release in the airways. Because these
mediators are key components of allergen-
induced airway responses, we wanted to
determine if toxin challenge would induce a
LAR and AHR similar to that seen with aller-
gen. We also wanted to determine if preexpo-
sure to toxin could accentuate the response to
allergen or if allergen challenge affected the
response to toxin. We found that although
PbTx-3 (20 breaths of 100 pg/mL) caused an
early bronchoconstriction, there was no sub-
sequent LAR or AHR in sheep that demon-
strated these responses to inhaled allergen
(data not shown). To determine if toxin expo-
sure would enhance the response to allergen
and/or affect the postantigen-induced AHR,
we exposed three sheep to PbTx-3 (20 breaths
of 100 pg/mL) for 3 consecutive days and
then, on the day 4, measured the response to
allergen challenge. On the next day, we mea-
sured their PC400 to carbachol to determine
if the postantigen-induced AHR was affected.
Figure 5 shows that the 3-day exposure to
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Figure 1. Effect of pharmacologic agents on breve-
toxin-induced bronchoconstriction. Crude breve-
toxins produced an immediate increase in RL, which
then returned to baseline values within 1 hr.
Pretreatment with atropine, budesonide, albuterol,
and diphenhydramine all reduced the toxin-induced
response. Values are mean ± SE for ﬁve sheep. 
*p < 0.05 versus all others; #p < 0.05 albuterol versus
diphenhydramine.
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Figure 3. Effect of the bradykinin B2 receptor antag-
onist HOE-140 on crude brevetoxin–induced bron-
choconstriction. Animals treated with HOE-140 had
a reduced response compared with that seen
when the animals were untreated (Un). The
response in the presence of HOE-140 was similar to
that seen with diphenhydramine (Diphen) but less
than that seen with atropine (Atr). Values are
mean ± SE for ﬁve sheep. 
*p < 0.05 versus untreated; #p < 0.05 versus HOE-140.
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Figure 2. Reversal of crude brevetoxin–induced
bronchoconstriction with albuterol. Values are
mean ± SE for ﬁve sheep. 
*p < 0.05 versus untreated.PbTx-3 did not alter the airway responses to
allergen (EAR, LAR, or AHR) in these ani-
mals when compared with the control allergen
responses in these same sheep.
Although preexposure to PbTx-3 did not
accentuate antigen-induced responses, aller-
gen challenge did increase the sensitivity to
PbTx-3. Figure 6 shows that the concentra-
tion–response curve for PbTx-3 was signifi-
cantly enhanced 24-hr after allergen exposure
in sheep that develop a LAR (138 ± 9%). The
sheep were also hyperresponsive to carbachol
at this time as evidenced by the decrease in
the post challenge PC400 (15 ± 1 breath
units) when compared with the prechallenge
PC400 (28 ± 2 breath units, p < 0.05). These
data suggest that, as seen with other irritants,
the airways are more sensitive to toxin after an
asthma exacerbation.
Discussion
The results of this study conﬁrm and extend
our previous work with brevetoxin aerosols
(Abraham et al. 2005). We conﬁrm that both
cholinergic and histamine H1-mediated path-
ways contribute to the bronchoconstrictor
responses to toxin at concentrations 10–100
times greater than those used previously
(Abraham et al. 2005). In addition, we identi-
ﬁed standard asthma medications that protect
against and/or reverse the constrictor effects of
inhaled toxin. Our previous work showing
that cromolyn sodium can block toxin-induced
constrictor effects (Abraham et al. 2005) in
conjunction with our current evidence that
both the airway and cutaneous responses to
toxin are histamine mediated, provides further
support for the hypothesis that toxin activates
mast cells in vivo. We show that kinins are
released in the airways after toxin inhalation.
This is a novel ﬁnding and, combined with the
demonstration that the response to inhaled
toxin is greater in inflamed airways, suggests
that kinins could be contributing factors to the
reported increased sensitivity of asthmatic
patients to toxin exposure.
The methodology used in the airway
provocation studies is designed to deliver
toxin directly into the lung under controlled
conditions. Although this technique does not
mimic natural exposures because it bypasses
the upper airways, it provides a reproducible
controlled airway challenge system that elimi-
nates dosing variability. This reproducibility
is an important consideration when studying
adverse lower airway effects and identifying
protective pharmacologic agents. Given this,
our ﬁndings should be applicable to humans
experiencing lower airway symptoms during a
red tide event.
Field studies indicate that humans with
normal or healthy airways as well as those
with compromised airways respond to a red
tide event (Backer et al. 2003, 2005; Fleming
et al. 2005; Kirkpatrick et al. 2004). Data
from our previous study, using both allergic
and nonallergic sheep, are consistent with
these observations (Abraham et al. 2005). We
found that the constrictor response to
aerosolized brevetoxins was not limited to
allergic animals. Normal (i.e., nonallergic)
animals responded with a dose-dependent
bronchoconstrictor response to inhaled toxin,
and although there was tendency for the aller-
gic animals to be more responsive, the differ-
ence was not significant. The similarity in
responsiveness between the two groups was
attributed to the fact that the allergic sheep
had not seen allergen during the course of the
studies and so the inflammatory status of
their airways was similar to that of the nonal-
lergic animals (Abraham et al. 2005).
However, when the airways of allergic sheep
are inflamed, as is the case after an antigen
challenge (Abraham et al. 1994, 2000), the
response to brevetoxin is enhanced (Figure 6).
Thus, the response to toxin is not linked to
the allergic status per se but is affected by the
inﬂammatory status of the airways at the time
of toxin exposure.
Even though toxin can elicit respiratory
symptoms in both normal and compromised
airways, a major aim of the present study was
to identify asthma medications that could
provide protective and/or therapeutic effects
against toxin-induced bronchoconstriction.
We used crude brevetoxins for these studies
because we considered this aerosol more rele-
vant to natural exposures experienced by per-
sons living in coastal areas. To provide a
more severe stimulus, higher concentrations
of toxin were administered than used previ-
ously. The constrictor responses to PbTx-3
and crude brevetoxins at concentrations 10-
to 100-fold lower were similar to those seen
here and were inhibited by cromolyn
sodium, atropine, and diphenhydramine
(Abraham et al. 2005). Although atropine
and diphenhydramine are not considered
standard therapy for the treatment of asthma,
the findings that these drugs blocked the
responses to an increased toxin burden are
important because they conﬁrm that the pro-
tective effects seen previously were not dose
dependent and that the same mechanisms are
operative at higher toxin levels. Pretreatment
with inhaled budesonide and albuterol pro-
vided signiﬁcant protection against the toxin-
induced bronchoconstriction. Acutely
administered, the glucocorticosteroid budes-
onide is not a bronchodilator nor does it
affect cholinergic responsiveness; therefore,
its acute protective effects may be related to
the drug’s ability to prevent mast cell activa-
tion in vivo (Denburg 1997; Kamada and
Szefler 1995). This action would reduce the
histaminergic component of the response. β2
adrenergic agents, in addition to their bron-
chodilatory activity, can also reduce mediator
release (Wanner et al. 1987); therefore, such
a mechanism could contribute to and possi-
bly explain the slightly enhanced protection
afforded by albuterol (Figure 1). The bron-
chodilatory activity normally attributed to β2
adrenergic agents is illustrated in Figure 2,
where the albuterol is shown to reverse the
toxin-induced bronchoconstriction. The
latter effect is relevant to affected individuals
Mini-Monograph | Airway effects of brevetoxins
Environmental Health Perspectives • VOLUME 113 | NUMBER 5 | May 2005 635
**
*
*
20 min
60 min
140
120
100
80
60
40
20
0
Crude PbTx PbTx-3 CrudePbTx+H1A PbTx-3+H1A
S
u
r
f
a
c
e
 
a
r
e
a
 
(
m
m
2
)
Figure 4. Effect of the histamine H1-antagonist
diphenhydramine (H1A) on the ICRs to crude breve-
toxins (PbTx) and PbTx-3. Values are mean ± SE for
nine sheep. 
*p < 0.05 versus untreated.
600
500
400
300
200
100
0
30
25
20
15
10
5
0
LAR
EAR
R
L
 
(
%
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
)
Time (hr)
–2 0 2 4 6 8 10
Control
PbTx-3–treated
A Control
PbTx-3–treated
BSL Postantigen
P
C
4
0
0
 
(
b
r
e
a
t
h
 
u
n
i
t
s
)
B
*
*
Figure 5. (A) The effect of 3 consecutive days of PbTx-3 exposure on antigen-induced EAR (early increase
in RL, 0–4 hr) and LAR (late increase in RL, 4–8 hr; and (B) AHR to carbachol (indicated by the decreased
PC400 24 hr after challenge). PbTx-3 exposure (20 breaths of 100 pg/mL) had no effect on any parameter.
Values are mean ± SE for three sheep. 
*p < 0.05 versus baseline.that require rescue medication when exposed
to aerosolized red tide toxins.
We previously reported that inhalation
challenge with a variety of noxious agents
results in increased tissue kallikrein activity and
subsequent kinin generation in the airways.
Increased kinin levels are associated with bron-
choconstriction, inflammation, and AHR
(Forteza et al. 1994, 1996; Scuri et al. 2000).
Kinins also cause airway wall edema, which can
inﬂuence the relaxation of the airways after a
contractile stimulus (Wagner 1997). Asthmatic
subjects are more sensitive to the effect of
inhaled kinins than are normal individuals
(Fuller et al. 1987). Inhaled bradykinin caused
cough and retrosternal discomfort in both nor-
mal and asthmatic subjects, but caused bron-
choconstriction only in the asthmatics (Fuller
et al. 1987). Interestingly, this difference in
kinin sensitivity could explain why Backer
et al. 2003, 2005) were unable to demonstrate
pulmonary function changes in normal sub-
jects exposed to toxin even though they com-
plained of chest discomfort, as opposed to
Fleming et al. (2005), who were able to
demonstrate pulmonary function changes in
toxin-exposed asthmatics. Thus, kinin genera-
tion could be a contributing mechanism
responsible for the heightened sensitivity of
asthmatic subjects to toxin. Our data showing
that the bradykinin B2 receptor antagonist
HOE-140 significantly reduced the bron-
choconstrictor response to inhaled toxin sug-
gest that toxin stimulated increased kinin levels
in the airway. These ﬁndings may be of greater
consequence in terms of repeated exposures
where increased kinins could contribute to
inflammation and AHR (Zaias et al. 2004).
Given the increased sensitivity of asthmatics to
bradykinin (Fuller et al. 1987), our findings
suggest that activation of the kinin pathway by
brevetoxins could be another mechanism that
contributes to more severe responses in
patients with compromised airways.
In allergic sheep, the ICR to injected
A. suum antigen is mast cell mediated, and
antihistamines block this response (Ahmed
et al. 1993; Lucio et al. 1992). We have used
skin tests in combination with inhalation chal-
lenge tests to demonstrate that tryptase acti-
vates mast cells (Molinari et al. 1995, 1996).
The data suggesting that inhaled toxin stimu-
lates airway mast cells/basophils led us to test
this hypothesis in the skin. Both crude breve-
toxins and PbTx-3 induced ICRs, which were
significantly reduced in the presence of
diphenhydramine. These findings provide
additional evidence that toxin activates mast
cells in vivo. We should caution, however, that
although the collective airway and skin data
strongly argue in favor of mast cell hypothesis,
ﬁnal validation must be withheld until hista-
mine measurements are obtained from lung
and skin ﬂuids. Nevertheless, if the ﬁndings in
the airways and skin can be extrapolated to
humans, then one might speculate that nor-
mal subjects, who would not generally have
access to inhaled steroids and/or β2 adrener-
gics, might obtain relief from toxin-induced
irritation with antihistamines.
The collective data from the skin and the
airways prompted a number of questions
regarding toxin-allergen interactions. These
questions were precipitated by reports of
adverse respiratory events hours after the origi-
nal toxin exposure in susceptible individuals.
In an attempt to mimic this scenario in the
laboratory, we determined if a single toxin
exposure could stimulate the development of a
LAR and AHR, similar to that seen with aller-
gen. We were unable to demonstrate this
effect. Similarly, we were unable to show that
exposures for 3 consecutive days to PbTx-3
accentuated the response to allergen. These
ﬁndings indicate that, although toxin elicits an
acute bronchoconstriction, the stimulus and/
or signaling mechanisms are not the same as
seen with allergen that can result in a LAR and
AHR. Furthermore, under the conditions of
the experimental protocol, repeated toxin
exposure was an insufﬁcient stimulus to prime
the airways such that the response to allergen
challenge was augmented. We did find that
allergen challenge accentuated the response to
toxin. The increased responsiveness occurred
during the period when the airways are
actively inﬂamed and when they demonstrate
increased responsiveness to other constricting
agents, as seen previously (Abraham et al.
1994, 2000) and here with carbachol.
Although the data in the present study
were generated in an acute setting, there is a
parallel to the more chronic situation that
exists in asthmatics whose airways are chroni-
cally inﬂamed and have heightened sensitivity
to a variety of nonspeciﬁc bronchoconstrictors.
Thus, the contention that the airways of asth-
matics may be more sensitive to inhaled toxins
than those of persons with normal airways may
depend, in part, on the status of airway
inﬂammation at the time of exposure.
In summary, we have provided new data
concerning the airway effects of inhaled breve-
toxins. We have identiﬁed clinical drugs that
may be useful in the prevention and treatment
of toxin-induced bronchial responses.
Conﬁrmation of these results must await con-
trolled clinical trials. Nevertheless, given the
caveat that these ﬁndings are based on experi-
mental data collected in animals, our results
may be of benefit to individuals affected by
aerosolized brevetoxins at environmentally
relevant levels.
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